2025-11-16 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data. I'll break it down into sections, present the numbers, and then offer a brief interpretation.

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 51.06%
*   **VOO Cumulative Return:** 98.45%
*   **Absolute Divergence (JNJ - VOO):** -56.6%
*   **Divergence Range:**
    *   Max: 16.6%
    *   Min: -65.5%
    *   Current: -56.6%
*   **Relative Divergence:** 10.8

**Analysis:** JNJ has significantly underperformed the S&P 500 over the tracked period. The negative absolute divergence shows this underperformance, and the relative divergence places it in the lower range of its historical performance compared to the index.

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
| ----------- | ------ | ------ | ------ | ---- | ------ |
| 2015-2017 | 26.0%  | 66.8%  | -2.0%  | 0.0  | 336.6  |
| 2016-2018 | 14.0%  | 10.7%  | -1.0%  | 0.1  | 310.9  |
| 2017-2019 | 20.0%  | 71.5%  | -2.0%  | 0.4  | 351.4  |
| 2018-2020 | 19.0%  | 79.2%  | -4.0%  | 0.4  | 379.2  |
| 2019-2021 | 33.0%  | 79.2%  | -14.0% | 0.5  | 412.2  |
| 2020-2022 | 8.0%   | 79.6%  | 9.0%   | 0.4  | 425.6  |
| 2021-2023 | -19.0% | 79.6%  | -21.0% | 0.3  | 377.6  |
| 2022-2024 | -32.0% | 79.6%  | -53.0% | 0.3  | 348.4  |
| 2023-2025 | 22.0%  | 79.6%  | -41.0% | 0.1  | 472.1  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Highly variable depending on the time frame. Recent periods (2021-2025) show negative or weak growth.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant potential for losses from peak to trough.
*   **Alpha:** Mostly negative, meaning JNJ has generally underperformed its benchmark on a risk-adjusted basis.  There is a single recent period of positive alpha.
*   **Beta:** Low, suggesting JNJ is less volatile than the overall market.
*   **Cap(B):** Market capitalization fluctuates but generally shows growth over time.

### 2. Recent Stock Price Movement

*   **Current Price:** 195.93
*   **Previous Close:** 195.25
*   **Change:** 0.35 (Slightly up)
*   **5-Day Moving Average:** 193.56
*   **20-Day Moving Average:** 190.18
*   **60-Day Moving Average:** 184.48

**Analysis:** The stock price is currently above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend. The positive change from the previous close reinforces this.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 63.32 (Approaching overbought territory)
*   **PPO (Percentage Price Oscillator):** 0.29
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Divergence Change:** 5.9 (+), indicating short-term upward momentum.
*   **Expected Return:** -179.8% (Long-term, vs. S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates the stock is nearing overbought conditions.
*   The positive change in relative divergence suggests recent outperformance relative to its past performance compared to the S&P 500.
*   The very negative expected return is a significant concern, suggesting substantial underperformance compared to the S&P 500 over a long-term investment horizon.
*   The small price change (0.35) doesn't suggest a significant volatility event.

### 4. Recent News & Significant Events

*   **Positive:**
    *   [2025-11-16] Johnson & Johnson (JNJ) Emerges as Scotiabank’s Top Pick for Curative Treatments
*   **Negative/Neutral:**
    *   [2025-11-14] Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail (Sector Impact)
    *   [2025-11-14] Sector Update: Health Care Stocks Ease Late Afternoon
    *   [2025-11-14] Sector Update: Health Care Stocks Fall Friday Afternoon
    *   [2025-11-14] US Equity Indexes Mixed as Technology Rebound Helps Lift Nasdaq, S&P 500 (Broader Market Context)

**Analysis:** Recent news is mixed. The Scotiabank recommendation is a positive signal. However, broader sector weakness and general market volatility may create headwinds.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 2.16 (~Buy)
*   **Opinions:** 24 analysts
*   **Target Price (avg/high/low):** 200.82 / 230.00 / 155.00
*   **Recent Rating Changes:** Not specified

**Analysis:** Analysts, on average, have a "Buy" rating for JNJ, with a mean target price slightly above the current price. This suggests potential upside, although the range of target prices is wide.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출        |
| ------------ | ---- | ----------- |
| 2025-10-22   | 2.14 | 23.99 B$    |
| 2025-07-24   | 2.3  | 23.74 B$    |
| 2025-04-23   | 4.57 | 21.89 B$    |
| 2024-10-23   | 1.12 | 22.47 B$    |
| 2025-10-22   | 1.12 | 22.47 B$    |

**Analysis:**

*   **Revenue:** Fluctuates slightly but generally shows stability, with a recent peak.
*   **EPS (Earnings Per Share):** Highly variable, with a significant spike in 2025-04-23. The repeating entry for 2025-10-22 and 2024-10-23 with identical values is unusual and should be verified.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | --------------- |
| 2025-09-30   | $23.99B   | 69.56%        |
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
| ------------ | --------- | ------- |
| 2025-09-30   | $79.28B   | 6.50%   |
| 2025-06-30   | $78.47B   | 7.06%   |
| 2025-03-31   | $78.11B   | 14.08%  |
| 2024-12-31   | $71.49B   | 4.80%   |
| 2024-09-30   | $70.16B   | 3.84%   |

**Analysis:**

*   **Revenue:** Consistent and strong revenue generation.
*   **Profit Margin:** High and relatively stable, indicating good operational efficiency.
*   **Equity:** Growing steadily, demonstrating increased net worth.
*   **ROE (Return on Equity):** Fluctuates, with a peak in 2025-03-31, but generally indicates reasonable profitability relative to equity.

### 7. Overall Analysis

Johnson & Johnson presents a mixed picture. Here's a summary:

*   **Underperformance:**  Historically, JNJ has significantly underperformed the S&P 500. The expected return suggests this trend may continue.
*   **Financial Strength:** The company has strong and consistent revenue, high profit margins, and growing equity.
*   **Analyst Sentiment:** Analysts are generally positive on the stock, with a "Buy" consensus and a target price slightly above the current level.
*   **Technical Signals:** Short-term momentum appears positive, but the RSI suggests it may be approaching overbought territory.
*   **Risk:** High maximum drawdowns, but low beta values.

**Conclusion:** While JNJ exhibits financial stability and is favored by analysts, its historical underperformance compared to the S&P 500 and the negative expected return are significant concerns. Investors should weigh the company's stability and analyst optimism against its relative underperformance before making an investment decision.
